1259396-11-6

Basic information

• Product Name: Methyl 5-broMo-2-Methylthiophene-3-carboxylate
• Synonyms: Methyl 5-broMo-2-Methylthiophene-3-carboxylate;5-Bromo-2-methyl-thiophene-3-carboxylic acid methyl ester;Methyl5-bromo-2-methylthiophene
• CAS NO: 1259396-11-6
• Molecular Formula: C7H7BrO2S
• Molecular Weight: 235.09828
• Mol File: 1259396-11-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 5-broMo-2-Methylthiophene-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-broMo-2-Methylthiophene-3-carboxylate(1259396-11-6)
• EPA Substance Registry System: Methyl 5-broMo-2-Methylthiophene-3-carboxylate(1259396-11-6)

Safety Data

• Hazardous Substances Data: 1259396-11-6(Hazardous Substances Data)

Usage

General Description

Methyl 5-bromo-2-methylthiophene-3-carboxylate is a chemical compound with the molecular formula C8H7BrO2S. It is a derivative of thiophene, which is a five-membered aromatic ring containing four carbon atoms and one sulfur atom. The presence of the bromine and methylthio groups in this compound gives it unique reactivity and properties. It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Due to its potential for biological activity and diverse applications, this compound is of interest to researchers in the fields of medicinal chemistry, organic synthesis, and drug discovery.

Upstream product

• 1918-78-1 2-methylthiophene-3-carboxylic acid 
• 53562-51-9 2-methylthiophene-3-carboxylic acid methyl ester 
• 88-13-1 3-Thiophene carboxylic acid 

Downstream Products

• 1334598-73-0 C₁₃H₁₂O₄S₂ 
• 1334598-77-4 C₁₃H₁₁NO₃S 
• 1334598-01-4 C₂₀H₁₈N₂O₂S₂ 
• 1334598-04-7 C₂₁H₂₀N₂O₂S₂ 
• 1334598-15-0 C₁₉H₁₅N₃O₂S 
• 1334598-18-3 C₁₉H₁₈N₂O₃S₃ 
• 1334598-23-0 C₁₉H₁₇N₃O₂S₂ 
• 1334598-64-9 C₁₄H₁₂O₃S 
• 1467070-68-3 N-cyclopropyl-2-methyl-5-[(E)-3-oxo-3-[[2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl]amino]prop-1-enyl]thiophene-3-carboxamide 
• 1467070-89-8 methyl 2-methyl-5-[(E)-3-oxo-3-[[2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl]amino]prop-1-enyl]thiophene-3-carboxylate 
• 1467070-88-7 2-methyl-5-[(E)-3-oxo-3-[[2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl]amino]prop-1-enyl]thiophene-3-carboxylic acid 

Relevant articles and documents

Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus

Glucokinase (GK) is an enzyme that plays an important role as a glucose sensor while maintaining whole body glucose homeostasis. Allosteric activators of GK (GKAs) have the potential to treat type 2 diabetes mellitus. To identify novel GKAs, a series of compounds based on a thiophenyl-pyrrolidine scaffold were designed and synthesized. In this series, compound 38 was found to inhibit glucose excursion in an oral glucose tolerance test (OGTT) in mice. Optimization of 38 using a zwitterion approach led to the identification of the novel GKA 59. GKA 59 exhibited potent blood glucose control in the OGTT test as well as a favorable safety profile. Owing to low pancreatic distribution, compound 59 primarily activates GK in the liver. This characteristic could overcome limitations of other GKAs, such as hypoglycemia, increased plasma triglycerides, and loss of efficacy.

Novel ASK1 inhibitor and application thereof

The invention relates to a compound shown as a general formula (I), a pharmacologically acceptable salt, ester or a stereisomer. The invention also relates to a preparation method of the compound, a medicine preparation containing the compound and a medic

COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.